



COPY OF PAPERS
ORIGINALLY FILED

57453-C/JPW/ADM/PL

Marked-up Version of Amendments

Deletions to the text are indicated by square brackets.

In the Claims:

198. (Amended) A method of treating depression [and/or anxiety] in a subject which comprises administering to the subject a composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a MCH1 antagonist, wherein:
- (a) (1) the MCH1 antagonist does not inhibit the activity of central monoamine oxidase A greater than 50 percent, at a concentration of 10mM; and
(2) the MCH1 antagonist does not inhibit the activity of central monoamine oxidase B greater than 50 percent, at a concentration of 10mM; and
- (b) the MCH1 antagonist binds to the MCH1 receptor with a binding affinity at least ten-fold higher than the binding affinity with which it binds to each of the following transporters: serotonin transporter, norepinephrine transporter, and dopamine transporter.

Applicants: John A. Salon et al.
Serial No: 09/899,732
Filed: July 5, 2001
Exhibit 3